Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy

Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancer cases. Due to the lack of expression of well-known molecular targets [estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)], there is a need for more alternative treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaib, Tahir, Cheng, Ke, Liu, Tingdang, Mei, Ruyi, Liu, Qin, Zhou, Xiaoling, He, Lifang, Rashid, Hibba, Xie, Qingdong, Khan, Hanif, Xu, Yien, Sun, Pingnan, Wu, Jundong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917013/
https://www.ncbi.nlm.nih.gov/pubmed/36768478
http://dx.doi.org/10.3390/ijms24032152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917013/
https://www.ncbi.nlm.nih.gov/pubmed/36768478
http://dx.doi.org/10.3390/ijms24032152

Ejemplares similares